Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | PKM | P14618 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | PYGL | P06737 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | DHODH | Q02127 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | PYGM | P11217 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4605963 | 0.87 | PKM (0.58) | GAAPKMKDM4EALDH1A1HSD17B10 | |
| SCHEMBL4604249 | 0.80 | POLB (0.54) | GAAPKMKDM4EALDH1A1HSD17B10 | |
| SCHEMBL4605407 | 0.80 | PYGM (0.60) | GAAPKMKDM4EALDH1A1HSD17B10 | |
| SCHEMBL4603406 | 0.78 | GAA (0.53) | GAAPKMKDM4EHSD17B10POLB | |
| SCHEMBL4605617 | 0.78 | PYGM (0.74) | GAAPKMALDH1A1HSD17B10MEN1 | |
| SCHEMBL14075341 | 0.75 | ALDH1A1 (0.65) | GAAPKMKDM4EALDH1A1MEN1 | |
| SCHEMBL4603683 | 0.74 | PYGM (0.62) | MEN1KMT2APYGLSMN1; SMN2PYGM | |
| SCHEMBL4604342 | 0.74 | KDM4E (0.49) | GAAPKMKDM4EALDH1A1HSD17B10 | |
| SCHEMBL4606880 | 0.74 | KMT2A (0.57) | PKMKDM4EALDH1A1HSD17B10MEN1 | |
| SCHEMBL4604961 | 0.73 | ALDH1A1 (0.48) | GAAPKMKDM4EALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1720825-B1 | ANTHRANILIC ACID DERIVATIVES, METHODS FOR THEIR PREPARATION AND USE AS DHODH INHIBITORS | ACTIVE BIOTECH AB (SE) | 2008-07-09 | — | — | EP | disclosed |
| US-7074831-B2 | Compounds, methods for their preparation and use thereof | ACTIVE BIOTECH AB (SE) | 2006-07-11 | — | — | US | disclosed |
| US-20050187297-A1 | New compounds, methods for their preparation and use thereof | ACTIVE BIOTECH AB (SE) | 2005-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187297-A1 | New compounds, methods for their preparation and use thereof | MALT1, TPMT, FUCA1 | GAA 864/4885PKM 2002/4885KDM4E 2898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.